Related Experiment Video
Updated: May 1, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer
1Clinical Oncology, Velindre Hospital, South East Wales Cancer Centre, Whitchurch, Cardiff, South Glamorgan, UK. richard.adams@velindre-tr.wales.nhs.uk
Abstract:
The discovery over 20 years ago by the Nobel Laureate Stanley Cohen of epidermal growth factor and its receptor, followed by the recognition that this receptor is overexpressed in multiple cancer types, has been of phenomenal significance. From these events the 'Holy Grail' of targeted therapy has looked increasingly realistic. Over the last 5 years this work has come of age with the licensing of multiple agents targeting this important mitogenic pathway in multiple tumor types. However, these agents and the technology behind them, while impressive, have resulted in lower clinical response rates than anticipated. In this review we will focus on the epidermal growth factor receptor-targeted therapies in colorectal cancer, why our expectations from these therapies have not yet been fulfilled and how we may predict those cancers that are likely to respond or be resistant to these therapies through a greater appreciation of the intricacy, diversity and dynamism of cellular signaling mechanisms.
Insights
Epidermal growth factor receptor (EGFR) targeted therapies show promise for colorectal cancer but have lower response rates than expected. Understanding complex cellular signaling is key to predicting treatment success.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- The discovery of epidermal growth factor (EGF) and its receptor (EGFR) has been significant in cancer research.
- EGFR is overexpressed in many cancer types, leading to the development of targeted therapies.
- Recent years have seen the approval of multiple agents targeting the EGFR pathway in various tumors.
Purpose of the Study:
- To review EGFR-targeted therapies in colorectal cancer.
- To explore reasons for lower-than-anticipated clinical response rates.
- To discuss predicting patient response or resistance based on cellular signaling.
Main Methods:
- Review of scientific literature on EGFR-targeted therapies.
- Analysis of clinical response rates in colorectal cancer.
- Exploration of cellular signaling pathways involved in EGFR signaling.
Main Results:
- EGFR-targeted therapies have been developed for multiple tumor types, including colorectal cancer.
- Clinical response rates for these therapies have been lower than initially expected.
- The complexity and diversity of cellular signaling mechanisms influence treatment outcomes.
Conclusions:
- Despite advancements, EGFR-targeted therapies in colorectal cancer face challenges in achieving expected response rates.
- A deeper understanding of intricate cellular signaling is crucial for predicting patient response and resistance.
- Future strategies may involve personalized approaches based on signaling pathway analysis.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase